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Abstract
Background. Celiac disease (CD) is an autoimmune disease that develops in patients with a genetic predisposition, incurring a
susceptibility to gluten-containing foods such as barley, wheat, and rye. The elimination of gluten from the diet is the main
therapeutic approach and usually leads to clinical and laboratory improvement. There are no ideal markers that objectively
assess dietary compliance in CD patients.
Materials and methods. Sixty newly diagnosed CD patients (male/female: 43/17) and 40 healthy subjects (male/female: 23/17)
were enrolled in this study. The diagnosis of CD was established by both histological ﬁndings of duodenum biopsy (total villous
atrophy and lymphocytic inﬁltration) and positive antibodies against endomysium or gliadin.
Results. A signiﬁcantly higher mean platelet volume (MPV) was observed in the CD group compared with healthy subjects
(8.45 ± 0.96 fL versus 7.93 ± 0.63 fL; p = 0.004). After introduction of a gluten-free diet, the MPV of CD patients in the dietary
adherent group was signiﬁcantly lower than that of the non-adherent group (8.09 ± 0.6 fL versus 8.9 ± 1.08 fL; p = 0.001).
Overall dietary adherence rate was 71.6% (43/60 CD patients). In the dietary compliant group, initiation of gluten-free
diet was associated with a signiﬁcant decrease in MPV from base-line values (8.56 fL versus 8.25 fL; p = 0.008). In the
non-adherent group, MPV on 3-month follow-up was higher than at base-line (8.05 fL versus 8.91 fL; p = 0.001).
Conclusion. MPV could be a promising and easily available biomarker for monitoring of dietary adherence in CD patients at a
low cost in comparison with other modalities.
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Introduction
Celiac disease (CD) is an autoimmune disease which
affects genetically predisposed individuals, making
them susceptible to gluten, which is found in foods
such as barley, wheat, and rye. Progressive inﬂam-
mation of the small intestine is the predominant
underlying pathology of the disease, eventually result-
ing in malabsorption if gluten-containing foods are
not restricted (1). A correct diagnosis is usually based
on the detection of serum antibodies against
endomysium and gliadin followed by histopatholog-
ical conﬁrmation by a biopsy of the small intestine,
using criteria described by Marsh (intraepithelial lym-
phocytes, villus atrophy, and crypt hyperplasia) (1–3).
Elimination of gluten from the diet is the main ther-
apeutic approach, resulting in signiﬁcant clinical and
laboratory improvements in the majority of CD
patients. None of the markers available today are
reliable indicators of dietary compliance in patients
with CD. Moreover, a group of patients present with
subtle clinical and laboratory abnormalities which
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CD in such patients is of great importance to prevent
the development of CD-related complications (osteo-
penia/osteoporosis and vitamin and mineral deﬁcien-
cies due to malabsorption), the most feared of which
being the development of T-cell lymphoma (5).
Mean platelet volume (MPV) has recently been
recognized as an inﬂammatory marker in various
conditions including ulcerative colitis, acute pancre-
atitis, and myocardial infarction (6–8). While some
studies demonstrated a negative correlation between
MPV and inﬂammatory activity, other investigators
have reported on an association between increased
MPV and disease severity. The relationship between
MPV and CD was ﬁrst reported by O’Grady et al. (9).
No study has so far reported MPV as a biomarker
for monitoring of dietary adherence in CD patients
over time. The purpose of the present study was to
evaluate the impact of MPV as a monitor of disease
severity in CD.
Materials and methods
This study was carried out between March 2009
and June 2010 on 60 newly diagnosed CD patients
admitted to the gastroenterology department of
Ankara Numune Education and Research Hospital.
A diagnosis of CD was established by positive anti-
bodies against gliadin and/or endomysium and con-
ﬁrmed with histological ﬁndings of duodenum biopsy
based on modiﬁed Marsh classiﬁcation (9,10).
The control group consisted of patients who were
diagnosed with functional gastrointestinal disorders,
all of whom had a normal complete blood cell count
(CBC), erythrocyte sedimentation rate (ESR), and
serum C-reactive protein (CRP) levels, as well as
being negative for antibodies against gliadin and
endomysium. Written informed consent was obtained
from all the participants in the study.
Patients with heart failure, peripheral vascular dis-
ease, acute or chronic infection, cancer, hematologic
and hepatic disorders, and a history of drug use
(non-steroid anti-inﬂammatory drugs, anticoagulant
medications, and oral contraceptives) were excluded
from the study.
All CD patients approached for inclusion into the
study were subjected to ultrasonographic examination
of the abdomen by an experienced operator using the
General Electric LOGIQ P5 device. A 3–5M H z
(3.5 C) convex transducer probe (General Electric
Healthcare,Milwaukee,WI)wasused forthe measure-
ments.The spleen sizewas evaluatedinthe right lateral
decubitus position. Measurements were obtained of
the splenic length with the maximum dimension
during suspended respiration. Splenic lengths of 80–
130 mm were considered as normal, and patients with
splenic atrophy were excluded from the study.
The implications of a diagnosis of CD were dis-
cussed at length with all patients, after which the
necessary gluten-free dietary recommendations were
given, with particular stress on the importance of
adherence.
A follow-up visit was scheduled for 3 months later
for each patient, when participants were asked to
complete a standard questionnaire regarding their
adherence to a gluten-free diet. Subjects were subse-
quently divided into two groups based on their
responses to questions on the questionnaire: Group
1 consisted of patients deemed adherent to a strict
gluten-free diet, whereas those with no or intermittent
adherence to the diet were placed in Group 2.
All CBC analyses were performed in the hematol-
ogy laboratory of our hospital. All CBC analyses both
on admission and at control were performed within
2 hours of blood sample collection with the use of a
Beckman Coulter (High Wycombe, UK) Gen-S auto-
mated analyzer.
The Statistical Package for Social Sciences (SPSS)
for Windows
  v. 17 was used for all statistical anal-
yses. All data were given as mean values plus/minus
SD. For continuous variables, the Mann–Whitney
U test was used to analyze the variance among groups.
Chi-square test was used for comparison of categor-
ical variables. A p-value of 0.05 and below was
considered statistically signiﬁcant.
Results
Sixty CD patients (43 males, 17 females) and
40 healthy controls (23 males, 17 females) were
Table I. Demographic features of the patients and controls.
Patients (n = 60) Controls (n = 40) p
Age (years) 35.3 ± 12.4 40.1 ± 12.5 0.61
Gender F/M 43 (71.7%)/17 (28.3%) 23 (57.5%)/17(42.5) 0.143
Smoking +/- 20 (33.3%)/40 (66.7%) 12 (30%)/28 (70%) 0.94
Spleen size (mm) 92 ± 12 93 ± 11 0.86
Dietary adherence 47/60 (71.6%)
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clinical characteristics of all participants are summa-
rized in Table I. Mean age, gender distribution, and
smoking habits were similar in both groups. MPV in
initial diagnosis was signiﬁcantly higher in the CD
group compared to healthy controls (8.45 ± 0.96 fL
versus 7.93 ± 0.63 fL; p = 0.004) (Figure 1). Similarly,
patients in the CD group had a higher mean platelet
count compared to their healthy counterparts (346 
10
9/L versus 264  10
9/L; p = 0.001). Laboratory
values of the study population are summarized
in Table II.
Based on results of the questionnaire at the follow-
up visit at the third month, 43 of 60 (71.6%) CD
patients adhered to a strict gluten-free diet, compared
to 17 patients (29.4%) who were deemed non-adher-
ent. MPV of the adherent group was signiﬁcantly
lower than that of the non-adherent group (8.09 ±
0.6 fL versus 8.9 ± 1.08 fL; p = 0.001). In the dietary
compliant group, introduction of a gluten-free diet
resulted in a signiﬁcant decrease in MPV compared to
base-line (8.56 fL versus 8.25 fL; p = 0.008). In the
non-adherent group, MPV at 3-month follow-up was
higher than the value at base-line (8.05 fL versus
8.91 fL; p = 0.001) .
Discussion
Our ﬁndings indicate that MPV was augmented in
patients with newly diagnosed CD compared to
healthy controls. Among CD patients, mean MPV
values showed a tendency towards normalization over
time in patients in the diet-adherent group. Con-
versely, in non-adherent patients and the patients
with intermittent transgressions, the mean MPV value
continued to increase from the starting value.
CD is a chronic inﬂammatory disorder and requires
life-long treatment and follow-up. Despite our under-
standing of new aspects of the disease, treatment
remains unchanged and constitutes elimination of
gluten from the diet (11). Dietary compliance is
generally based on patient self-reports, and there
are very few objective criteria to evaluate the dietary
compliance among CD patients. Although demon-
stration of histological improvement is the generally
accepted gold standard, this remains an invasive and
impractical method for the routine follow-up of a
selected group of patients (12). Until now, a reliable,
non-invasive measure of dietary adherence has not
been described. Follow-up of antibody titers, partic-
ularly against tissue transglutaminase (Ttg), endomy-
sium, and gliadin, has been proposed as a good
indicator of transgressions in CD patients. However,
there are some limitations in routine clinical practice
(13,14). For example, certain disorders (autoimmune
hepatitis, giardiasis, refractory CD) may result in
persistently high antibody titers, making the interpre-
tation of results quite difﬁcult (5). Furthermore, anti-
bodies against endomysium and Ttg may not be
helpful in detecting minor or intermittent transgres-
sions in CD patients. On a similar note, some patients
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Figure 1. Comparison of MPV values between patients and healthy
controls on admission.
Table II. MPV and other inﬂammatory markers in patients and controls.
Patients (n = 60) Controls (n = 40) p
MPV (fL) 8.45 ± 0.96 7.93 ± 0.61 0.004
Platelet count ( 10
9 /L) 346 ± 121 264 ± 71 0.001
CRP (mg/L) 3.05 ± 1.22 3.1 ± 1.0 0.148
ESR (mm/h) 17.7 ± 17.4 16.4 ± 11.7 0.156
WBC count ( 10
9 /L) 7.0 ± 1.72 7.5 ± 2.01 0.245
CRP = C-reactive protein; ESR = erythrocyte sedimentation rate; MPV = mean platelet volume; WBC = white blood cell.
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initial diagnosis, and a delayed return to normal levels
in such cases may mislead clinicians (5,15).
Many hematology analyzers have included MPV
measurement in their repertoire, giving some infor-
mation about platelet activation and function. In
recent years, some studies have investigated a possible
association between MPV and several inﬂammatory
conditions such as myocardial infarction, stroke, dia-
betes, ulcerative colitis, chronic hepatitis B, and acute
pancreatitis (6,8,16,17). Yuksel et al.(6) reported low
levels of MPV to be related to more severe activity in
ulcerative colitis patients, postulating that MPV may
be equal to other conventional markers as an indicator
of disease severity. Conversely, in a study by
Klovaite et al. (18) increased MPV was found to be
an independent risk factor for myocardial infarction.
Based on these conﬂicting reports, it would seem that
both high and low MPV have a diagnostic and prog-
nostic value for different inﬂammatory conditions.
Our study results are consistent with ﬁndings
reported by O’Grady et al.(19), where the MPV
values of three groups (CD patients, normal controls,
and splenectomized patients) were compared. The
authors discovered that CD patients with intact
spleens had higher MPV values and platelet counts.
However, these investigators did not evaluate the
effect of a gluten-free diet on MPV.
The high MPV values observed in our study group
of newly diagnosed CD patients may be a reﬂection of
on-going intestinal inﬂammation; while on the other
hand, normalization of MPV values with the intro-
duction of a gluten-free diet may indicate resolution
of intestinal inﬂammation.
Our data suggest that MPV could be a promising
and easily available biomarker for monitoring the
dietary adherence of CD patients at a low cost in
comparison with other modalities.
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